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Summary 
The human malaria parasite Plasmodium falciparum is acquiring resistance to 
most drugs it has encountered, including the recently deployed Artemisinin 
Combination Therapy, on which much hope has been laid. Molecular markers for 
monitoring the evolution of resistance are, therefore, urgently required. Our group 
has recently made use of a rodent malaria model to identify a number of novel 
genetic markers of antimalarial drug resistance, namely a clathrin mu adaptor 
gene (pfcmu) involved in artemisinin resistance and an amino acid transporter 
gene (pfaat1) underlying chloroquine resistance. 
The main aim of this thesis was to characterize and evaluate the contribution of 
the above genes to drug resistance in natural parasite populations of P. falciparum 
isolates from three endemic areas: Rwanda, Democratic Republic of Sao Tomé & 
Principe (DRSTP) and Brazil. 
The global diversity of pfcmu and pfaat1 was determined, resulting in the 
identification of several polymorphisms. The pfaat1 gene appears to be highly 
conserved and no correlations were found between this gene and the in vitro 
resistance to 4-aminoquinolines. In contrast to pfaat1, the pfcmu gene was 
genetically diverse, with nine Single Nucleotide Polymorphisms and three 
different insertions identified across all isolates inspected. Samples could be 
grouped in to fourteen different pfcmu haplotypes, whose diversity was higher in 
both African sites than in Brazil (Hd = 0.964 ± 0.077, 0.750 ± 0.139 and 0.250 ± 
0.180 in Rwanda, DRSTP and Brazil, respectively). Some of the identified 
polymorphisms showed geographical specificity. We found a significant 
association between a pfcmu G479A genotype in Rwanda samples and the in vitro 
sensitivity to dyhidroartemisinin (p = 0.0207). These constitute new findings to 
suggest that polymorphisms in pfcmu can be involved in P. falciparum defence 
mechanisms against artemisinin derivatives. Thus, further assessment of the gene 
in artemisinin responses is a top priority, in the context of effective surveillance of 
artemisinin resistance.  
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Resumo 
A resistência do parasita Plasmodium falciparum aos fármacos é um dos 
principais obstáculos a uma contenção eficiente da malária. Os compostos 
utilizados para o combate a esta doença têm perdido sua eficácia ao longo dos 
anos, incluindo a artemisinina e os seus derivados, recentemente indicados como 
promissores no tratamento da malária. De facto, foram descritos recentemente os 
primeiros casos de resistência in vivo a estes compostos em parasitas de malária 
humana. Consequentemente, a identificação de marcadores moleculares de 
resistência a estes fármacos, previamente a um alastramento da resistência, 
apresenta-se como uma estratégia essencial. 
Recentemente, fazendo uso de um modelo de malária de roedores (Plasmodium 
chabaudi), o nosso grupo identificou um número de determinantes genéticos de 
resistência a diferentes antimaláricos, nomeadamente, o gene pfcmu, que codifica 
uma subunidade mu do complexo adaptador de clatrina e se relaciona com 
resistência aos derivados da artemisinina e o gene pfaat1, que codifica uma 
proteína transportadora de aminoácidos e está envolvido na resistência à 
cloroquina.  
O objectivo primordial deste trabalho centrou-se na caracterização dos genes 
acima descritos e na avaliação do seu possível papel em mecanismos de 
quimio-resistência em populações parasitárias provenientes de três regiões 
endémicas: Ruanda, República Democrática de São Tomé e Príncipe (RDSTP) e 
Brasil. 
Identificaram-se e caracterizaram-se os polimorfismos existentes em ambos os 
genes. O gene pfaat1 mostrou ser um gene altamente conservado e não revelou ter 
qualquer relação com a resistência às 4-aminoquinolinas. Pelo contrário, o gene 
pfcmu revelou possuir uma maior diversidade genética, tendo-se identificado nove 
mutações pontuais e três inserções, no conjunto de todos os isolados estudados. As 
amostras analisadas permitiram constituir catorze haplótipos, cuja diversidade 
demonstrou ser mais elevada nos países Africanos em comparação com o Brasil 
(Hd = 0,964 ± 0,077, 0,750 ± 0,139 e 0,250 ± 0,180 no Ruanda, RDSTP e Brasil, 
respectivamente). Alguns dos polimorfismos identificados revelaram 
 especificidade geográfica. Identificou-se uma associação significativa entre uma 
mutação no gene pfcmu (G479A) e a susceptibilidade in vitro à 
dihidroartemisinina, em isolados provenientes do Ruanda (p = 0.0207). 
Estes resultados sugerem que polimorfismos no gene pfcmu podem estar 
envolvidos nos mecanismos de resistência do parasita P. falciparum aos derivados 
da artemisinina. Por conseguinte, estudos futuros envolvendo este gene e as 
respostas aos derivados da artemisinina, revestem-se de especial importância no 
contexto actual de uma vigilância eficaz da resistência a estes compostos.  
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Chapter 1: Introduction 
1.1. The burden of malaria 
Despite considerable scientific advances and the development of modern drugs, 
malaria remains an important public health concern, affecting approximately 3 
billion people, and resulting in 250 million clinical cases each year. Although it is 
disseminated throughout more than 100 countries, the bulk of this burden falls on 
sub-Saharan Africa with about 90% of all malaria cases and related deaths1. 
The effect of malaria extends far beyond this direct measure of mortality since 
morbidity in endemic countries leads to major socio-economic losses. Acute 
febrile illness, anaemia, chronic debilitation, complications in the course and 
outcome of pregnancy, and delays in cognitive and physical development 
contribute to a heavy public-health burden, which has a negative impact on the 
social and economic development of affected countries2-6. The disease contributes 
to approximately 1.3% annual reduction of economic growth in countries with 
high levels of transmission7. 
 
1.2. Plasmodium 
Malaria is caused by protozoan parasites of the genus Plasmodium, which are 
inoculated into humans by female Anopheles mosquitoes. The genus contains 
more than 100 species of which four are infectious to humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale8. 
However, recent reports from Asia suggest the possibility that a different malaria 
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species, Plasmodium knowlesi, which usually infects primates, is on the verge of 
crossing the species barrier9. 
These species differ morphologically, immunogenically, in their geographical 
distribution, in their ability to relapse and in their response to drugs. By far, the 
most virulent specie is P. falciparum, which causes the majority of severe malaria 
morbidity and mortality10. 
 
 
1.3. Life cycle of Plasmodium falciparum 
The P. falciparum life cycle comprises numerous transitions stages and occurs 
between two separate hosts (Figure 1.1). The cycle begins when haploid 
sporozoites are injected into the human host by an infected female mosquito of 
the genus Anopheles during a blood meal. These motile forms of the parasite 
rapidly access the blood stream and then migrate to the liver. There, each 
sporozoite traverses a few hepatocytes, before finally establishing in one of them11, 
where it differentiates and undergoes asexual multiplication resulting in tens of 
thousands of merozoites which burst from the hepatoctye. Upon release from the 
liver, individual merozoites invade red blood cells (erythrocytes). Once inside the 
erythrocyte, P. falciparum develops into a ring stage/early trophozoite and then 
into a highly metabolically active late stage trophozoite. Finally, trophozoites 
develop into schizonts and asexual replication occurs. In the latter, new 
merozoites are formed within the schizont and are released to the bloodstream 
when the erythrocyte bursts. The clinical manifestations of malaria are associated 
with the synchronous rupture of infected erythrocytes. The free merozoites go on 
2 
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to invade additional erythrocytes. Although the majority of invading merozoites 
will go on to develop into schizonts and continue the asexual cycle, a small 
proportion enter the sexual phase of the life cycle by differentiating into haploid 
male or female gametocytes, which are the only forms that are transmissible to 
the mosquito.  
For transmission to occur, when an infectious host is bitten by a female 
anopheline mosquito, both male and female gametocytes must be taken up during 
the blood meal. Inside the mosquito midgut, gametocytes develop into gametes 
and sexual reproduction takes place, whereby 8 flagellated microgametes are 
released from a male gametocyte. These fertilize the female macrogamete to form 
a diploid zygote that converts into an ookinete which penetrates a cell wall in the 
midgut and subsequently develops into an oocyst. Each oocyst produces haploid 
sporozoites by asexual reproduction. The oocyst finally ruptures to release a large 
number of sporozoites into the haemolymph where from they eventually migrate 
to the mosquito salivary glands. The sporozoites remain here, ready to be 
inoculated into the next host and begin a new cycle of infection when the female 
mosquito takes a further blood meal. 
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Figure 1.1. The life cycle of P. falciparum (adapted from Rosenthal12)  
 
 
1.4. Malaria control 
Three living entities are involved in the malarial infection; parasite, host and 
vector. In order to reduce the burden of malaria, interventions can be designed to 
target several stages of the parasite lifecycle. For example, the parasite can be 
targeted in the host either directly with drugs, or indirectly with vaccines. 
4 
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Similarly, strategies that reduce vector contact with the host or increase vector 
mortality can be employed to reduce the number of new infections13. 
Despite decades of intensive research, no effective vaccine capable of 
conferring an adequate level of immunity has been developed to date10,14,15,16. 
Thus, measures aimed against the parasite are based on the use of drugs either as 
treatment or as prophylaxis. Medication reduces morbidity and mortality by 
terminating a malaria infection in a patient and restricts malaria transmission by 
diminishing the parasite reservoir7. Antimalarial drugs are also used as a 
preventive measurement, both as chemoprophylaxis for travellers to malaria 
endemic areas and for intermittent preventive treatment (IPT) in high-risk groups 
such as pregnant women, infants and children17,18. 
There are two key approaches to malaria prevention by vector control: the use 
of insecticide-treated nets (ITNs) and indoor residual spraying (IRS). These 
central interventions may be complemented by other methods such as larval 
control or environmental management18,19. 
 
1.5. Antimalarial drug resistance 
Antimalarial drugs remain as one of the most powerful tools in the fight against 
malaria. So far, malaria control has relied largely on a comparatively small 
number of chemically related drugs belonging to 7 classes of compounds: 
4-aminoquinolines, 8-aminoquinolines, arylaminoalcohols, antifolate compounds, 
artemisinin and derivatives, inhibitors of the respiratory chain and antibiotics20,21. 
 
 
5 
Chapter 1 - Introduction 
 
Table 1.1. Main groups of antimalarial compounds according to their chemical class 
 
Class Compound 
Chloroquine 
4-aminoquinolines 
Amodiaquine 
8-aminoquinolines Primaquine 
Quinine 
Mefloquine 
Halofantrine 
Arylaminoalcohols 
Lumefantrine 
Sulfadoxine 
Dapsone 
Pyrimethamine 
Proguanil 
Antifolates 
Chlorproguanil 
Artemisinin 
Artesunate 
Artemether 
Arteether 
Artemisinin and derivatives 
Dihydroartemisinin 
Atovaquone 
Inhibitors of the respiratory chain 
Proguanil 
Doxycyclin 
Antibiotics 
Clindamycin 
  
 
In recent decades, increases in malaria mortality rates in African children have 
been linked with the emergence and spread of parasites resistant to the 
antimalarial drugs in use22-26. Now, resistance to virtually all classes of 
antimalarial drugs is widespread in Africa and Southeast Asia.  
Until recently, chloroquine was the most widely used drug to treat and prevent 
malaria infection. The success of chloroquine was based upon its rapid action, 
safety and low cost relative to other antimalarials3. With the spread of chloroquine 
6 
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resistance, many countries adopted sulfadoxine-pyrimethamine (SP) combination 
as first line antimalarial treatment. Still, resistance to SP spread more rapidly than 
to chloroquine and is now widespread in Asia and South America and is spreading 
in Africa27.  
 
Drug combinations, rather than monotherapy, are now regarded as the best 
solution for treating malaria. The simultaneous use of two or more drugs is a 
chemotherapeutic strategy for improving treatment efficacy and retarding the 
development of resistance to the individual drugs in the combination28. The 
underlying principle for the impact of combination therapy on drug resistance is 
based on the assumption that drug resistance essentially depends on mutation. 
Provided that the constituent drugs administered in the combination have 
independent modes of action, the probability of a parasite developing resistance to 
both drugs simultaneously is significantly reduced compared to developing 
resistance to one drug. The probability that a mutant will arise that is at the same 
time resistant to two different antimalarial drugs is the product of the mutation 
rates per parasite for the individual drugs, multiplied by the number of parasites 
that are exposed to the drugs, in an infection29. 
In response to the increasing burden of malaria caused by P. falciparum 
resistance to the standard antimalarial medicines, World Health Organization 
(WHO) recommended the use of combination therapies, ideally those containing 
artemisinin derivatives in countries where P. falciparum malaria is resistant to the 
conventional antimalarial medicines chloroquine, SP, and amodiaquine28. 
Unfortunately, even artemisinin derivatives, the only drugs that had been fully 
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effective against P. falciparum until very recently, seem to be loosing their 
efficacy along the border between Cambodia and Thailand30-32. 
 
1.6. Artemisinin-based combination therapy 
Artemisinins are currently the most important class of antimalarial drugs, 
presenting many advantages over other compounds. These advantages include 
several possible routes of administration, suitability for treating severe malaria 
replacing quinine and avoiding its side effects, rapid activity and activity against 
trophozoites, blood schizonts, and also against ring forms and gametocytes33. This 
latter property may help diminish transmission rates34. Altogether, artemisinin 
derivatives reduce the incidence of malaria, reduce drug use, and thus contribute 
to slowing the evolution of drug resistance34,35. 
Artemisinin-based combination therapy (ACT), the combination of an 
artemisinin derivative with another structurally unrelated antimalarial, is now 
being proposed as the best therapeutic alternative for treating drug-resistant 
malaria and delaying the development of resistance17. 
Artemisinins are highly effective, short-acting drugs derived from an herb, 
qinghao (Artemisia annua), a plant found in China. This class of compounds can 
reduce the number of parasites faster than any other class of antimalarial drug and 
this is also the reason for their ability to provide clinical relief fast36,37.  
Because of the short elimination half-lives of the artemisinin compounds, the 
administration of artemisinins with longer-acting agents is required38. In an ACT, 
the artemisinin derivative kills rapidly and drastically most of the parasites and 
those that remain are then eliminated by a high concentration of the longer-lasting 
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partner drug, after the short-lived artemisinin has dropped below therapeutic levels. 
In this way the artemisinin derivative should protect its partner drug. If the 
treatment is successful, the partner drug also protects the artemisinin derivative by 
removing all the remaining parasites that were initially exposed to the artemisinin. 
Consequently the probability that mutant parasites survive and emerge from these 
two drugs is low37,39. However, this question is under debate. Accordingly to 
Hastings and Watkins, combination therapies containing drugs with mismatched 
half-lives could jeopardize the efficacy of the artemisinins, in particular 
combination with partner drugs against which resistance is already spread40. 
Discrepancy in the half-lives of the partner drugs leaves windows of monotherapy 
during which parasites can acquire resistance, or those with pre-existing resistance 
to the partner drug, re-emerge and cause drug failure. Ideally, drugs with short 
half-lives should be preferred, in order to reduce the exposure of reinvading 
parasites to suboptimal drug levels which may induce the selection for tolerance 
and eventually the development of resistance. 
 
1.7. Assessment and monitoring of resistance 
Drug surveillance is necessary to ensure correct management of clinical cases 
and early detection of changing patterns of resistance to assure that national 
treatment policies remain effective41. Three approaches have been used to evaluate 
the efficacy of an antimalarial drug: clinical in vivo studies (also known as 
therapeutic efficacy testing), in vitro susceptibility testing, and more recently, 
molecular markers.  
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In discussing these different approaches, it is fundamental to differentiate 
intrinsic parasite resistance from decreased clinical efficacy. The term resistance 
means the ability of a drug to prevent parasite growth in culture, at defined drug 
concentrations, and in the absence of the host immune response. Alterations in 
efficacy are detected through clinical in vivo studies in which parasite intrinsic 
susceptibility is one of several factors that determine the outcome42. 
1.7.1. In vivo tests  
The therapeutic efficacy test remains the “gold standard” method for detecting 
drug resistance41. These tests reveal the exact biological nature of drug treatment 
response. This response involves a complex interaction between the drugs, the 
parasites, and the host response (i.e. the therapeutic response of currently 
circulating parasites infecting the current population in which the drug will be 
used), while in vitro tests measure only the interaction between the parasites and 
the drugs43. 
In vivo tests involve the treatment of symptomatic P. falciparum infected 
patients with a standard dose of an antimalarial drug and subsequent follow-up of 
clinical and parasitological outcomes of treatment during a fixed period. Recent 
studies describe the benefits of 28-day, or even 42-day, follow-ups44. This 
proceeding allows the detection of any reappearance of symptoms or signs of 
clinical malaria and the detection of parasites in the blood as an indication of 
reduced sensitivity to a particular drug41. 
Due to the influence of factors such as the patient immunity, variations of drug 
absorption and metabolism, and possible misclassification of new infections as 
recrudescences, the results of therapeutic efficacy test do not necessarily reflect 
10 
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the real level of antimalarial drug resistance. These studies include others 
drawbacks: the long duration of patient monitoring that may result in high patient 
loss to follow-up, the assessment of resistance to one drug regimen only and poor 
ability to compare different studies, because local adaptations and modifications 
of the standard protocol are usually made42. 
However, these tests provide decision-makers with a simple, readily 
comprehensible indicator of the efficacy of an antimalarial drug with reduced 
requirement for equipment and supplies41. 
 
1.7.2. In vitro tests 
The in vivo method has allowed the thresholds of treatment failure that are 
crucial for adjusting antimalarial drug policies to be determined but it not 
sufficient on its own to confirm drug resistance41. 
To support the evidence of a failing antimalarial, an in vitro test can be used 
providing a more accurate measure of drug sensitivity under controlled 
experimental conditions, which removes variables such as patient immune status, 
re-infection and pharmacokinetics. In vitro tests allow a more objective approach 
to parasite resistance, since in these studies the parasite will be in direct contact 
with incremental drug concentrations. Several tests can be carried out with the 
same sample, and several drugs can be studied at the same time, including drugs 
that are still at the experimental stage41. 
Several in vitro tests exist, which differ with respect to the measure effect and 
the duration of exposure to the test compound. These include microscopic 
examination of blood films for the WHO mark III test (inhibition of maturation or 
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replication; Giemsa-stained), the radioisotopic test (incorporation of hypoxantine) 
and the enzyme-linked immunosorbent assay with antibodies directed against 
Plasmodium lactate dehydrogenase or histidine-rich protein II45.  
The importance of these tests has become evident with the increasing use of 
combination therapy, since they can be used to monitor susceptibility to each drug 
in a combination. It is often impossible to perform in vivo tests for each 
component, due to ethical problems, non-availability of the drug as monotherapy 
and the need to study a large number of patients46. 
Although this method is useful, its application is limited. In vitro methods 
require trained personnel with access to a laboratory capable to perform culture of 
malaria parasites. Even when provided with such facilities, it is often difficult to 
establish cultures and not all the primary parasites will adapt to in vitro culture 
conditions47. Moreover, in part because these tests remove the host factors, the 
correlation between results of in vitro and in vivo tests is not always reliable and is 
not well understood. In vitro drug sensitivity data may provide early evidence of 
increasing drug tolerance prior to parasitological/clinical resistance. Whereas, may 
give misleading indications if the alterations in sensitivity are so small that they do 
not result in parasitological/clinical resistance48. 
 
These limitations of in vivo and in vitro methods have led to the search for 
genetic markers of resistance. 
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1.7.3. Molecular markers 
Molecular markers for drug resistant malaria provide promising public heath 
tools of great potential value49. Studies that can detect genetic markers of drug 
resistance are relatively fast, quantitative and less expensive compared with 
clinical studies involving more patient care and follow-up50. In addition, collection, 
storage and transport of specimens for subsequent molecular analysis are far easier 
than for in vitro tests41. 
Molecular markers for drug resistance malaria are based on genetic changes 
that confer parasite resistance to drugs. These genetic mechanisms of 
P. falciparum drug resistance have not been completely elucidated. However, five 
genes that appear to play a role in regulation of resistance to the principal 
chemical families of antimalarials in current use have been identified. Multiple 
mutations in the P. falciparum chloroquine resistance transporter (PfCRT) confer 
resistance to chloroquine. In particular a substitution at amino acid position 76 (K 
to T)51,52 is crucial to the manifestation of in vitro resistance as well as therapeutic 
failure. Mutation in the P-glycoprotein homologue (Pgh1) encoded by pfmdr1 (P. 
falciparum multidrug resistance gene 1) may further modulate the extent of 
chloroquine resistance53. Polymorphisms and/or amplification of pfmdr1 have also 
been shown to affect the susceptibility to structurally unrelated antimalarial drugs, 
including mefloquine, artesunate, lumefantrine and quinine34,52. Resistance to 
sulphadoxine and pyrimethamine (SP) is conferred by mutations in the 
dihydropteroate synthase (pfdhps) and dihydrofolate reductase (pfdhfr) genes, 
respectively55,56. One mutation in the plasmodial ATPase6 gene has been proposed 
as a marker for artemisinin resistance but this association has not yet been 
confirmed57. 
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As it is the case with in vitro tests, the presence of particular molecular markers 
does not necessarily directly predict treatment outcome. Mutations in the above 
genes contribute to drug failure but the outcome is not certain: some patients with 
“resistant” alleles clear the infection, and some patients with “sensitive” alleles 
failed treatment. Therefore is better to think in terms of mutations encoding rising 
probabilities of drug failure that ultimately depends on factors such as host 
immune response, the drug dose taken, and variation in drug absorption and 
metabolism58. 
 
Much debate has occurred concerning the relative qualities of one test over 
another, with the suggestion always being that one type of test should be used 
preferentially. These methods can be considered as complementary sources of 
information about resistance, rather than competing, regarding the different types 
of information each approach gives. 
 
1.8. Mechanisms of drug resistance 
The development of resistance is a two steps process; de-novo emergence and 
subsequent spread. Resistance arise through point mutations or gene duplications, 
mainly during asexual reproduction, a single genetic event may be all that is 
required, or multiple events (epistasis). The rare de-novo emergence event is 
thought to be independent of drug selection pressure59. These mutants are then 
selected for survival, multiplication, and subsequent spread as a result of the drug 
pressure which provides a selective advantage to resistant parasites2,59,60. Resistant 
parasites are then transmitted to other individuals by mosquitos61. In addition, 
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sometimes mosquitoes bite two gametocyte-carrying humans offering the 
possibility of recombination with the formation or breakdown of multigenic 
resistance2. The parasites carrying the mutant alleles are selected if antimalarial 
drug concentrations are sufficient to inhibit the development of susceptible 
parasites but are insufficient to inhibit the mutants, a phenomenon known as "drug 
selection"62. 
Advances in the understanding of the mechanisms of drug action during the 
last two decades led to the identification of the putative molecular targets and the 
genetic basis responsible for parasite resistance to antimalarial drugs. The genetic 
events that confer antimalarial drug resistance include single point mutations in or 
changes of copy numbers of genes encoding drug targets, such as important 
enzymes or pumps that affect intraparasitic drug concentrations.  
 
In the following sections the genes implicated in the resistance to the drugs 
investigated in this thesis, the 4-aminoquinolines and artemisinins derivatives, are 
described in detail. 
 
1.8.1. Genes influencing 4-aminoquinolines 
susceptibility 
Resistance to 4-aminoquilolines is multigenic and relates to changes in drug 
accumulation in the parasite’s food vacuole. In 2000, the P. falciparum 
chloroquine resistance transporter (pfcrt) gene was identified as a primary 
candidate gene for chloroquine resistance by extensive mapping of genetic cross 
between chloroquine sensitive and resistant clones. A single nucleotide 
polymorphism (SNP) at position 76 (replacement of lysine by threonine), has been 
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reported to be completely associated with chloroquine resistance in 40 laboratory-
adapted P. falciparum clones from wide geographic areas51. Other pfcrt mutations 
occur, but their patterns tend to vary in different geographical areas and their role 
remains undetermined63. The causal relationship between pfcrt mutations and 
chloroquine resistance was further confirmed by genetic transfection 
experiments64. Several in vivo studies showed total selection of the pfcrt K76T 
mutant allele in clinical failure65. However, the presence of parasites carrying this 
allele was not always predictive of the clinical outcome or predictive of in vitro 
resistance66-68. This mutation appears to be a prerequisite for resistance but may 
not be sufficient on its own69,70. 
In addition to mutations in pfcrt, polymorphisms in the P. falciparum multidrug 
resistance gene 1 (pfmdr1) have been suggested to modulate the degree of 
resistance in parasites harbouring the pfcrt T76 mutation71. Transfection and 
allelic exchange tests have shown strong associations between pfmdr1 
polymorphisms and enhancement of the degree of in vitro chloroquine resistance72. 
However, many clinical studies have failed to find associations between pfcrt and 
pfmdr1 mutations and chloroquine resistance67,73,74 and isolates carrying the same 
pfcrt and pfmdr1 genotypes often reveal different IC50 values, indicating that 
several other genes may also be responsible for the increase level of chloroquine 
resistance75. 
 
This suggests involvement of additional genetic loci in modulating chloroquine 
resistance, more studies are necessary to elucidate the mechanisms of resistance to 
this class of drugs.  
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1.8.2. Genes influencing artemisinin susceptibility 
Some scientists have questioned whether resistance to artemisinin would ever 
arise. However, the recent cases of resistance reported, characterized by slow 
parasite clearance in vivo, indicate that these assumptions where wrong30-32. The 
specific mechanism of action of artemisinin is not well understood, and there is 
ongoing research directed at elucidating it. Uhlemann and colleagues provided 
strong evidence that resistance to artemisinins may depend on a single nucleotide 
polymorphism in the drug’s putative chemotherapeutic target, the SERCA-type 
ATPase protein of P. falciparum (PfATPase6)76. A subsequent study report that P. 
falciparum parasites from French Guiana harboring mutant forms of the 
pfATPase6 gene (S769N) displayed significantly increased IC50s to artemisinins, 
suggesting its role in artemisinin resistance57. However, mutations in this gene are 
not associated with resistance in field isolates from elsewhere. Moreover, our 
group could not identify any mutation or altered copy numbers of the ATPase6 
gene in artemisinin and artesunate-resistant clones of P. chabaudi. Causal 
unequivocal association between mutations in the pfATPase6 gene and resistance 
to artemisinins has not yet been established though, whilst other genes have also 
been implicated in this phenotype. 
Amplification of the multi-drug resistance 1 gene has been linked to the 
parasite’s ability for modulating artemisinin responses in previous work53,77,78. In 
an attempt to clarify the role of pfmdr1 amplification in this phenotype, Sidhu et 
al.79 genetically abolished one of the two copies of the gene in the multi-drug 
resistant parasite P. falciparum FCB. In vitro assessment of the resulting 
knock-out mutant harboring a single gene copy revealed that its response to 
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artemisinin had approximately halved, providing the first direct evidence as to the 
ability of pfmdr1 copy number to modulate this phenotype. 
Surprisingly, no correlation was found between pfATPase6 and pfmdr1 genes 
and in vivo resistance to artemisinins in the first confirmed cases of resistance 
along the Thai/Cambodian border31,80. Thus we still lack validated genetic markers 
to monitor the evolution of artemisinin resistance in natural parasite populations. 
Significant efforts should now be directed at elucidating the mechanisms of 
parasite resistance to this class of compounds, in order to develop strategies that 
allow maximizing their useful longevity. 
 
 
1.9. Plasmodium chabaudi model system 
Field studies of human malaria parasites provide very limited amount of 
information about the mechanisms underlying drug resistance. Consequently, the 
genetic basis of drug resistance in malaria must be investigated by other ways. 
One of the most appropriate ways is to use genetically stable resistant mutants 
selected through drug pressure from cloned sensitive parasite lines. In this way, 
drug sensitive and drug resistant parasites are genetically identical (isogenic) 
except for the mutation involved in resistance; such mutations can then be 
identified using different approaches. In vitro studies with human malaria 
parasites present several limitations. Identification of causative mutations requires 
controlled in vivo laboratory experiments, which are simply not feasible with 
human malarias. Therefore rodent malaria parasites have been widely used to 
study the mechanisms of drug resistance in vivo81-85. Plasmodium chabaudi 
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chabaudi is a malaria parasite of murine rodents and it has been used as a model to 
study various aspects of parasite biology and disease which are difficult to 
investigate using human malaria parasites. There are many reasons why P. 
chabaudi is considered to be a good model for the human malaria parasite, 
especially in studies on drug resistance. This species shares a number of 
similarities in their basic biology with P. falciparum, including preferential 
invasion of mature erythrocytes, the synchronicity of their asexual blood form, 
sequestration of schizont-infected erythrocytes, and gametocyte development late 
in the infection86.  
Our group has determined the genetic basis of drug resistance in a congenic 
lineage of multi-drug resistant mutants of P. chabaudi, selected from sensitive 
progenitors, using advanced technology like Linkage Group Selection (LGS) and 
Solexa (second generation sequencing technology). LGS allows the identification 
of areas of the whole genome associated with drug resistant phenotypes, using the 
uncloned, recombinant progeny of genetic crosses87 and Solexa permit the rapid 
and accurate sequencing of whole parasite genomes and thus the identification of 
any mutation occurring within drug resistant clones88. 
These studies have identified three genes, two that could potentially mediate 
artemisinin resistance a de-ubiquitinating enzyme (ubp1)89 and an adaptor protein 
subunit (clathrin mu adaptor - cmu) (Cravo et al., unpublished); and one amino 
acid transporter (aat1) underlying chloroquine resistance (Cravo et al., 
unpublished). However, the importance of the above mentioned markers in 
modulating susceptibility to the different drugs in the human malaria parasite has 
not been assessed yet. 
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In the above context, the objective of this work was to evaluate the importance 
of two of these newly identified molecular markers of antimalarial drug resistante, 
the pfcmu and pfaat1 genes, in natural parasite populations of P. falciparum. To 
achieve this, we used an extensive collection of previously samples isolates of P. 
falciparum originating from 3 endemic regions (Rwanda, Democratic Republic of 
Sao Tomé & Principe and Brazil) which were tested for in vitro sensitivity to 
several drugs90-92. In these samples we investigated the correlation between the 
presence of mutations in the pfcmu and pfaat1 genes and the in vitro sensitivity to 
artemisinin derivatives and 4-aminoquinolines, respectively. 
 
1.10. Aims of the thesis 
 
The main aim of this thesis was to determine whether particular mutations in 
the pfcmu and pfaat1 genes can be used as molecular markers for predicting 
parasite’s in vitro responses to chloroquine and artemisinin derivatives. 
 
The specific aims were as follows: 
● To genotype sensitive and resistant parasites for single nucleotide 
polymorphisms in pfcmu and pfaat1 genes identified in our group. 
● To evaluate the potential role of these genes (mutations) as putative 
modulators of the resistance in P. falciparum.  
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2.1. Plasmodium falciparum isolates 
This study included the analysis of a collection of previously sampled isolates 
of P. falciparum which were freshly collected and tested in vitro for their response 
to several antimalarial drugs, as described below. 
Blood samples were collected in Rwanda during November and December 
200392, in the Democratic Republic of Sao Tomé & Principe (DRSTP) during 
February 200490 and in Brazil during September 200591. 
After confirming P. falciparum monoinfection each sample from DRSTP and 
Brazil was tested for its in vitro susceptibility to drugs, using a modified version 
of the standard WHO MarkIII micro-test93. The in vitro drug sensitivity of 
Rwanda isolates was assessed by use of a classical isotopic microtest technique94.  
Fifty six P. falciparum isolates from Brazil were characterized for the in vitro 
susceptibility to artesunate and artemether. A set of 74 isolates from Rwanda were 
characterized for their in vitro susceptibility to chloroquine, amodiaquine and 
dihydroartemisinin. The isolates from the DRSTP were characterize for their in 
vitro susceptibility to amodiaquine (53 isolates), artesunate (42 isolates) and 
artemether (51 isolates). 
The in vitro values of half maximal inhibitory concentration (IC50) were 
calculated and organized according to increasing concentrations. 
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2.2. DNA extraction 
DNA was extracted according to the method described by Plowe and co-
workers95. Briefly, dried filter paper (Whatman TM no. 4) onto which venous 
blood had been blotted and kept at room temperature was cut and placed into 
1.5 ml tubes. One millilitre of 10 % saponin in phosphate-buffered saline (PBS) 
was added to each tube. Tubes were then incubated overnight at 4 ºC and 
subsequently washed in PBS. Afterwards, genomic DNA from each sample was 
obtained by boiling in Chelex-100 followed by ethanol precipitation. DNA was 
stored at 4 ºC until use. A similar method was used to extract genomic DNA from 
the reference strain 3D7. 
 
2.3. Molecular analysis of drug-resistance associated genes 
2.3.1. Primer design 
The P. chabaudi chabaudi genes previously proposed as putative modulators of 
drug resistance were the following: clathrin mu adaptor gene (cmu) and amino 
acid transporter gene (aat1). The DNA sequences of these genes were available 
online at the PlasmoDB genome database (http://plasmodb.org/plasmo) with the 
following accession numbers: PCAS_143590 for pccmu and PCAS_112780 for 
pcaat1. In order to obtain the P. falciparum orthologues of the genes we used the 
genetic synteny maps provided by PlasmoDB (Figures 2.1 and 2.2). Individual 
gene sequences of P. falciparum orthologues were retrieved from the synteny 
maps and used as template for designing primers to amplify each open reading 
frame using an overlapping PCR fragment strategy.  
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Specie: Plasmodium chabaudi chabaudi
ID: PCAS_143590
Description: adaptor protein subunit, putative
Specie: Plasmodium falciparum 3D7
ID: PFL0885w
Description: adaptor protein subunit,  
putative
Chr12
Chr14
Chr14
Chr14
Chr14
Chr14
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Synteny map of the region surrounding PCAS_143590 gene [showing orthologous 
genes in P. falciparum, P. vivax, P. knowlesi, P. yoelii and P.berghei. The horizontal lines indicate 
the chromosomal backbone, with the chromosome number shown on the left. The bars indicate the 
genes. Genes with introns are shown has interrupted bars. The color of the bars indicate the 
direction of transcription; blue for forward and red for reverse transcription directions. Genes with 
sequence identity between species are connected by shaded gray lines. UTRs- Untranslated regions; 
M– mega base pairs; K– kilo base pairs (adapted from PlasmoDB)]. 
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Chr11
Specie: Plasmodium
ID: PCAS_112780
Description: amino 
putative
 chabaudi chabaudi
acid transporter,
Specie: Pl
ID: PFF14
Descriptio
putative
Chr6
Chr11
Chr11
Chr11
Chr11
asmodium falciparum 3D7
30C
n: amino acid transporter, 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Synteny map of the region surrounding PCAS_112780 gene [showing orthologous 
genes in P. falciparum, P. vivax, P. knowlesi, P. yoelii and P.berghei. The horizontal lines indicate 
the chromosomal backbone, with the chromosome number shown on the left. The bars indicate the 
genes. Genes with introns are shown has interrupted bars. The color of the bars indicates the 
direction of transcription; blue for forward and red for reverse transcription directions. Genes with 
sequence identity between species are connected by shaded gray lines. UTRs- Untranslated regions; 
M– mega base pairs; K– kilo base pairs (adapted from PlasmoDB)]. 
 
Primers were manually designed for each of the genes, according to the 
following parameters: avoidance of the formation of self and hetero-dimers, 
hairpins and self complementarity, primer length and melting temperature. These 
properties were verified using a primer design software, entitled Oligonucleotide 
Properties Calculator (http://www.basic.northwestern.edu/biotools/oligocalc.html). 
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Several primers were designed and used in order to amplify the whole genes 
and those producing positive results are shown in Table 2.1. These primers were 
then used in PCR amplifications, as described below. 
 
Table 2.1. Primer sequences and PCR reactions for pfcmu and pfaat1 genes. 
 
Gene Primers Sequence (5’ to 3’) Coordinates Length PCR Program 
    
PfClR-1F GTTAACACGATTAGCGTCATTTG 94 ºC, 3 min ;  
PfClR-2R GTCCTATTATGTATATGTGGATC [94 °C, 30 s; 53 °C, 45 s; 72 °C, 60 s;] 35 cycles 
  
(-54 to 524) 
578 bp 
72 °C, 10 min;  
    
PfClR-3F GATATCCACAAACATTAGAAGTG 94 ºC, 3 min ;  
PfClR-4R CCATCTGGTGGTGTGAAGG [94 °C, 30 s; 52 °C, 45 s; 72 °C, 60 s;] 35 cycles 
  
(358 to 1199) 
841 bp 
72 °C, 10 min;  
    
PfClR-5F GCATATTTCATCATTGTGTTACC 94 ºC, 3 min ;  
PfClR-6R ACACCCGATTGAACTATTTATAC [94 °C, 30 s; 53 °C, 45 s; 72 °C, 60 s;] 35 cycles 
pf
cm
u 
  
(1126 to 1879) 
753 bp 
72 °C, 10 min;  
    
Pfaat1-1F CATGAATATGTGAATCCTAAGT 94 ºC, 3 min ;  
Pfaat1-2R CTAATGACGAGGTACATAATATA [94°C, 30 s; 52 °C, 45 s; 72 °C, 60 s;] 35 cycles 
  
(-144 to 676) 
820 bp 
72 °C, 10 min;  
    
Pfaat1-3F CTGATGGGGATTATACTAATGAT 94 ºC, 3 min ;  
Pfaat1-4R CATGCATTTGGTTGTTGAGAG [94 °C, 30 s; 52 °C, 45 s; 72 °C, 60 s;] 35 cycles 
  
(418 to 1112) 
694 bp 
72 °C, 10 min;  
    
Pfaat1-5F CCATAACTGTATTAACTATAGGAC 94 ºC, 3 min ;  
Pfaat1-6R GATGTGATACCTCCTCCTATAC 94 °C, 30 s; 52 °C, 45 s; 72 °C, 60 s; 35 cycles 
  
(964 to 1661) 
697 bp 
72 °C, 10 min;  
    
Pfaat1-9F GATCCATACCAAGAAACACATG 94 ºC, 3 min ;  
Pfaat1-10R GTATGTTTTATTAAGCATCCTTC [94 °C, 30 s; 54 °C, 45 s; 72 °C, 60 s;] 35 cycles 
pf
aa
t1
 
  
(1479 to 2153) 
674 bp 
72 °C, 10 min;  
 
  
 
  
 
Positions of the primers, expected sizes of amplified products, and amplified 
gene regions are shown in Table 2.1. The primer coordinates were taken 
considering the A of the ATG start codon as base pair zero.  
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2.3.2. PCR 
A subset of P. falciparum isolates were initially selected according to their 
origin and response to each drug. These isolates were then inspected for changes 
in the sequence of each of the genes under investigation (Table 2.2). 
For the pfcmu gene we picked 8 samples from Rwanda, 8 from DRSTP, and 8 
from Brazil, in agreement with their response to artemisinin derivatives (4 samples 
with the lowest IC50 and the 4 with the highest values, from each country) (Table 
2.2). For the pfaat1 gene we selected 8 samples from Rwanda and 8 samples from 
DRSTP according to their response to 4-aminoquinolines (4 samples with the 
lowest IC50 values and the 4 with the highest, from each site) (Table 2.2). 
PCR assays were performed with 1 μl of DNA into a 50 μl mixture containing 
0.2 μM of each primer, 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates 
and 1.25 units of GoTaq® Flexi DNA Polymerase (Promega). 
PCR products were analysed by ethidium bromide-stained agarose 2 % gel 
electrophoresis.  
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Table 2.2. In vitro IC50 responses of a subset of P. falciparum isolates from Brazil, 
Rwanda and DRSTP, selected for genetic studies.  
 
Gene Site of Sample Collection Sample ID Drug 
IC50 
(nM) 
BR58 0.1 
BR05 0.2 
BR15 0.2 
BR45 0.2 
BR38 3.4 
BR07 4.8 
BR67 4.8 
Brazil 
BR68 
A
rte
su
na
te
 
4.9 
RW10 0.3 
RW32 0.3 
RW58 0.4 
RW30 0.5 
RW57 8.8 
RW106 9.6 
RW77 10.1 
Rwanda 
RW40 
D
ih
yd
ro
ar
te
m
is
in
in
 
14.3 
STP27 0.02 
STP29 0.03 
STP41 0.04 
STP46 0.05 
STP35 1.7 
STP34 2.0 
STP44 3.4 
pf
cm
u 
DRSTP 
STP58 
A
rte
su
na
te
 
9.0 
RW16 7.6 
RW10 8.9 
RW20 15.9 
RW12 17.3 
RW101 341.5 
RW103 348.9 
RW98 386.0 
Rwanda 
RW105 
C
hl
or
oq
ui
ne
 
443.7 
ST07 1.0 
ST19 1.0 
ST20 1.0 
ST28 1.0 
ST15 126.1 
ST13 129.3 
ST50 132.8 
pf
aa
t1
 
DRSTP 
ST58 
A
m
od
ia
qu
in
e 
156.0 
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2.3.3. DNA sequencing 
After DNA purification using a commercial kit (QIAquick PCR purification 
kit - QuiagenTM), amplified fragments were sequenced using the commercial 
services of Stab Vida (http://www.stabvida.com). DNA sequences were generated 
from both sense and antisense primers and aligned to check for genetic 
polymorphisms. Only unambiguous single nucleotide polymorphisms (SNPs) 
were considered. Potential sequence ambiguities were resolved through close 
inspection of the corresponding chromatogram, using ChromasPro software 
Version 1.5 (www.technelysium.com.au/ChromasPro.html). Sequences of 
insufficient quality were either resequenced or rejected. Sequence assembly was 
done manually or with the CAP3 Sequence Assembly Program available online 96. 
 
 
2.3.4. PIRA-PCR and RFLP 
One particular mutation in the pfcmu gene (G479A) was determined in all 
samples characterized for their in vitro response to artemisinin derivatives using a 
PCR-restriction fragment length polymorphism (RFLP) assay. Since this point 
mutation does not create a natural endonuclease restriction site, we investigated 
the possibility of using the primer-introduced restriction enzyme analysis PCR 
(PIRA-PCR) method. 
This method is based on incorporation of a deliberate mismatch in one primer 
so that a new restriction enzyme recognition site is created in the PCR amplicon in 
the presence of a specific allele in the target DNA. The programme available 
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online97 searches all mismatches on both sites of the mutation and on both strands 
and would create an artificial restriction site either for the wild-type (WT) or the 
mutant allele. 
A PIRA primer PfCLR-G479A-F (forward) with sequence 5'-ATC AAA TGA 
ATT ATT AAA TGT AAc TA -3' was thus designed, where an A-to-C mismatch 
was incorporated at the 3rd base position from 3' end terminus (shown in small 
letter in primer sequence). The terminal cTAG-3' sequence of the PIRA primer 
creates a recognition site for the restriction enzyme BcuI (Figure 2.3). 
For PIRA-PCR analysis, a PCR product was amplified using primers 
PfCLR-G479A-F and PfCLR-G479A-R (with sequence 5'- AAA ATG ATT TGC 
TGT CTT ATT A -3’) with final concentration of 0.2 μM, of each primer, 1.5 mM 
MgCl2, 0.2 mM deoxynucleoside triphosphates and 1.25 units of GoTaq® Flexi 
DNA Polymerase (Promega). Conditions of PCR were: initial denaturation at 
94 °C for 3 min, followed by 40 cycles of 94 °C for 30 s, 51 °C for 45 s and 72 °C 
for 60 s, and a final extension step of 72 °C for 10 min. 10 μl the PCR reaction 
mixture was digest with 20 units of BcuI restriction enzyme (Fermentas) with 
1 ×Buffer Tango in a final volume of 20 μl and incubated at 37 ºC for 3 h. The 
restriction products were run on 3 % agarose gel containing ethidium bromide and 
visualized by UV transillumination.  
Classification of each sample was made after inspection of its respective 
restriction pattern. 
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5’-TGTAAATA
3’-ACATTTATC-5’
WT
Mutant
5’-TGTAAA
G-3’
TA
3’-ACATTTATT-5’
5’-TGTAAc
A-3’
TA
3’-ACATTGATC
5’-TGTAAc
G-3’
-5’
TA
3’-ACATTGATT
A-3’
-5’
PIRA-PCR
PIRA-PCR
BcuI site 
(mismatch C)
(mismatch C)
Not BcuI site 
 
 
 
 
 
Figure 2.3. Diagram of PIRA-PCR. [Underling nucleotide is the local of the mismatch C 
introduction. The A to C mismatch incorporation is shown in small letter. The G479A single 
nucleotide polymorphism is coloured in red].  
 
2.4. Population genetics analysis 
Genetic diversity is generally measured as either “haplotype” or “nucleotide” 
diversity. Gene or haplotype diversity (i.e., the probability that two randomly 
selected haplotypes are present in the sample) looks only at the number and 
frequencies of haplotypes, whereas nucleotide diversity also includes a measure of 
haplotype sequence similarity. The nucleotide diversity (π), which is the average 
number of base differences per site between two homologous sequences randomly 
selected from a population, is an important parameter used to understand the 
structure and history of populations. Nucleotide variability was also measured 
using the population parameter Theta (θ), which considers the number of 
segregating sites (S) and the length of the sequences (i.e. the number of sites under 
study) and is one of the most important parameters in population genetics 
(http://www.ub.edu/dnasp/DnaSPHelp.pdf). 
Levels of genetic diversity were quantified using DnaSP 4.10 program 98. The 
following parameters were considered: N (sequences analysed), S (polymorphic 
sites), H (number of haplotypes), Hd (haplotype diversity) and its standard 
deviation (SD), π (nucleotide diversity) and SD and θ (Theta), the variability in a 
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population, calculated from S. Insertions and deletions were excluded from all 
estimates. 
 
2.5. Data analysis 
Peirce's criterion was used to test for and exclude statistical outliers. Peirce's 
criterion is a rigorous method, devised by Benjamin Peirce that may be used to 
eliminate suspect experimental data using probability theory99. This method was 
used to identify statistical outliers in the data used in genotype-phenotye 
association studies. 
The unpaired t-test was applied to assess the association between in vitro 
artemisinin derivatives response and the G479A mutation in the pfcmu gene. 
When P value < 0.05, result was considered as significant. Outliers were excluded 
from statistical analysis. 
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3.1. Identification and characterization of the Plasmodium 
falciparum clathrin mu adaptor and amino acid 
transporter genes and corresponding predicted proteins 
We aimed to identify and characterize the above genes in natural parasite 
populations of P. falciparum, namely: i) to define circulating genotypes in 
different endemic areas, ii) to investigate whether particular genetic 
polymorphisms could relate to differential parasite drug response levels and iii) to 
establish measures of genetic diversity and relatedness between genotypes from 
the different geographical sampling sites. 
The DNA sequences of the P. chabaudi cmu and aat1 orthologues were 
available online at the PlasmoDB database (http://www.genedb.org). In P. 
chabaudi, these genes are located on chromosome 14 and chromosome 11, 
respectively. According to the genetic sinteny map, the location of these genes in 
the rodent malaria parasite should correspond to blocks on P. falciparum 
chromosomes 12 and 6 in case of the cmu and aat1 genes, respectively. The P. 
falciparum orthologues of pccmu and pcaat1 genes were also available at the 
PlasmoDB database with the following accession numbers: PFL0885w and 
PFF1430c, respectively. These sequences were retrieved and used to design 
primers to amplify both genes, as described below. The information provided in 
this database revealed that the pfcmu gene is located on chromosome 12 of P. 
falciparum genome, as expected by genetic synteny. The gene is encoded by a 
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1866 nucleotide open reading frame which predicts a translated protein of 621 
amino acid residues with a deduced molecular mass of 72.9  kDa. 
The pfaat1 gene is located on chromosome 6 and the corresponding cDNA 
contains 2058 bp, with an expected structure comprising a single intron from base 
1676 to 1913. The deduced protein consists of 606 amino acids and has a 
predicted molecular mass of 68.8 kDa. 
 
3.1.1. Identification of conserved domains in the CMU 
and AAT1 predicted protein sequences 
The P. falciparum CMU and AAT1 predicted protein sequences were used to 
identify conserved protein families, using the Pfam database 
(http://pfam.sanger.ac.uk/), a reliable collection of protein families that includes 
their annotations and multiple sequence alignments generated using hidden 
Markov models. This database allows finding all known motifs that occur in a 
sequence.  
E-values (expectation values) were calculated and the resulting scores allowed 
the identification of a significant pfam-A match in each protein. The E-value is the 
number of hits that would be expected to have a score equal or better than this by 
chance alone (a good E-value is much less than 1). This significant match for the 
CMU predicted aminoacid sequence (E-value = 1.6e-64) corresponded to a protein 
domain family designated as Adaptor complexes medium subunit family (also 
known as mu homology domain) and located between residues 246-621 (Figure 
3.1). In the case of AAT1 we identified a protein domain family corresponding to 
a Transmembrane amino acid transporter protein (E-value = 1.2e-44), located 
between the residues 167-606 (Figure 3.1). 
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246
621 aaAdaptor complexes medium subunit family
167
606 aaTransmembrane amino acid transporter protein
P. falciparum CMU protein 
P. falciparum AAT1 protein 
These results provided additional confidence for the correct identification and 
retrieval of the genes under study.  
 
 
 
 
 
Figure 3.1. Graphical representation of potential Pfam domains of P. falciparum CMU and AAT1 
proteins. [Domains were predicted by sequence-motif approach using Pfam database 
(http://pfam.sanger.ac.uk/)]. 
 
3.2. Design and optimization of PCR 
In our study, we screened 40 field-collected isolates of P. falciparum from 3 
endemic regions (Brazil, Rwanda and DRSTP) for the presence of mutations in 
pfcmu and pfaat1 genes, using DNA sequencing. To do this, several primers were 
designed and used in novel PCR reactions in order to amplify and sequence the 
entire coding region of the two genes (see “Material and Methods” section for 
details). 
After optimization of the PCR conditions for each primer set, the size of the 
amplification products was estimated by comparison with a 100 bp molecular 
marker DNA ladder (MassRulerTM Low Range, Fermentas), in order to ensure that 
PCR products had the expected size. Typical results after assay optimization are 
shown in Figure 3.2 and in Figure 3.3 for pfcmu and pfaat1 gene, respectively.  
After several rounds of optimization all primer pairs produced the desired 
results except for pfaat1 7F/8R, which consistently failed to generate PCR 
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amplicons. Consequently a new set of, of primers targeting the same area of the 
gene, was designed (9F/10R). 
 
 
 
 
 
 
 
Figure 3.2. (Top) Ethidium bromide-stained 2 % agarose gel electrophoresis of pfcmu PCR 
products [obtained using the 1F/2R set of primers (A), the 3F/4R set of primers (B) or the 5F/4R 
set of primers (C) are represented. Lanes: L – 100 bp DNA ladder; 1 – Positive Control (3D7); 2, 3, 
4 - P. falciparum isolates randomly selected; 5 – Negative Control.] (Bottom) Schematic 
representation of pfcmu gene structure [showing each primer position and fragments size; Arrows 
indicate the position of the primers used to amplify the different fragments; F and R indicate the 
forward and reverse primers, respectively]. 
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Figure 3.3. (Top and Bottom) Ethidium bromide-stained 2 % agarose gel electrophoresis of 
pfaat1 PCR products [obtained using the 1F/2R set of primers (A), the 3F/4R set of primers (B), 
the 5F/4R set of primers (C) or the 9F/10R set of primers (D). Lanes: L – 100 bp DNA ladder; 
1 - Positive Control (3D7); 2, 3, 4, 5, 6- P. falciparum isolates randomly selected; 7 – Negative 
Control]. (Middle) Schematic representation of pfaat1 gene structure [showing each primer 
position and fragments size. Areas in black indicate the exon and arrows indicate the position of 
the primers used to amplify the different fragments. F and R indicate the forward and reverse 
primers, respectively]. 
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3.3. Characterization of gene mutations in Plasmodium 
falciparum isolates 
The PCR protocols above were applied to a subset of P. falciparum isolates 
previously selected according to their origin and response to each drug (see 
“Material and Methods” section for details). For the pfaat1 gene we selected 16 
samples, 8 from Rwanda and 8 from DRSTP according to their response to 
4-aminoquinolines. For the pfcmu gene we picked 24 samples, 8 from each 
country (Brazil, Rwanda and DRSTP) according to their response to artemisinin 
derivatives.  
In order to identify possible point mutations in these genes, the overlapping 
sequencing fragments were compiled to obtain a pfcmu and a pfaat1 sequence for 
each sample. All sequences thus generated were compared with the reference 
strain P. falciparum 3D7 to search for potential SNPs and insertions/deletions 
(indels). Sequence alignments were carried out using online software denoted 
Multiple Sequence Alignment with hierarchical clustering100. 
 
3.3.1.  Plasmodium falciparum clathrin mu adaptor gene 
Sequence analysis of the pfcmu gene revealed a total of 12 polymorphic sites, 
consisting of 9 SNPs and 3 indels. Details on the genetic polymorphisms 
identified in the pfcmu gene and the corresponding encoded amino acids are 
shown in Table 3.1. Briefly, among the 12 identified polymorphisms, 7 SNPs and 
all the insertions were novel mutations compared with the information available in 
PlasmoDB database (this database incorporates the recently completed P. 
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falciparum genome sequence and annotation, as well as SNPs analysis for several 
P. falciparum strains and isolates). 
Five (56 %) of these SNPs were non-synonymous mutations, causing changes 
in the amino acid sequence while 4 were synonymous mutations (Table 3.1). 
 
Table 3.1. SNPs identified in the pfcmu gene with their consequent amino acid 
replacements. 
 
Codon 
Reference 
sequence 
(3D7) 
Amino acid Nucleotide substituition 
Amino acid 
changes 
     
100 ATA Ile ATC  none 
127 GTG Val GTT*/GTC  none 
146 AGA Arg AAA Lys 
160 AGT Ser AAT Asn 
162 ATT Ile ATC  none 
163 GAA Glu GAG* none 
199 AAA Lys ACA Thr 
233 AAT Asn AAG  Lys 
437 TTC Phe TTA Leu   
 
* - SNP present in PlasmoDB database. SNPs with amino acid changes shown in bold type. 
 
All 3 indels observed lead to a 3-nucleotide insertion of the AAT codon that 
corresponds to an insertion of an asparagine residue in the polypeptide chain 
(Table 3.2). The insertions of the asparagine residues were found in 3 different 
stretches of asparagines.  
 
Table 3.2. Indels identified in pfcmu gene, nucleotide insertion and consequent additional 
amino acid. 
 
Codon Insertion Amino acid 
   
234 AAT Asn 
325 AAT Asn 
330 AAT Asn 
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Polymorphism distribution across functional domains 
In order to investigate the possible meaning of the polymorphic sites found in 
PfCMU we analysed their distribution according to protein domains. Among the 
12 mutations/insertions described only 3 lyed in the conserved Adaptor complex 
medium subunit family domain (Figure 3.4), namely, one non-synonymous 
mutation (F437L) and 2 insertions (325N and 330N). 
 
 
Adapto
P. falciparum CMU protein
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Figure 3.4. Schematic illustration of the described mutations/insertions in the context of functional 
domains of P. falciparum CMU protein. [The locations and the types of the 12 mutations/insertions 
are also shown]. 
 
Polymorphism distribution and prevalence 
Analysis of pfcmu DNA sequences showed that mutant alleles of this gene were 
present in 21 of 24 samples (87.5 %). The most common allele of the pfcmu gene 
in the field isolates of P. falciparum was 381T (21.9 %). Six of the 13 (46 %) 
polymorphisms identified were infrequent, with the variant-type alleles occurring 
only in one isolate (singletons). Seven of the 8 (87.5 %) isolates from Brazil have 
the same sequence which differs from the 3D7 reference strain in only one point 
mutation (G381T) (Table 3.3). The remaining P. falciparum isolate from Brazil 
had an identical sequence to the 3D7 reference strain.  
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The Rwanda samples presented the higher degree of polymorphism, with 8 
mutated sites affecting 8 codons and one insertion (Table 3.3). Six of the 
polymorphisms found were detected in only one P. falciparum isolate and variant 
alleles exist in frequencies ranging from 12.5% (1/8) to 37.5% (3/8). 
In the DRSTP, 3 polymorphisms (G381C, G479A and A489G) and 3 insertions 
were observed (Table 3.3). The 701AAT insertion was predominant, accounting 
for 4 of 8 isolates (50%). The insertion 987AAT and the A489G SNP were present 
in 2 of the 8 samples, respectively, whereas the other two SNPs and the 973AAT 
insertion were detected in only one isolate. 
 
Table 3.3. Prevalence of pfcmu mutations/indels identified in isolates of P. falciparum 
from Brazil, Rwanda and RDSTP. 
 
Codon Brazil (N=8) 
Rwanda 
(N=8) 
DRSTP 
(N=8) 
    
300C 0 2 (25.0 %) 0 
381T 7 (87.5 %) 0 0 
381C 0 0 1 (12.5 %) 
437A 0 1 (12.5 %) 0 
479A 0 3 (37.5 %) 1 (12.5 %) 
486C 0 1 (12.5 %) 0 
489G 0 1 (12.5 %) 2 (25.0 %) 
596C 0 1 (12.5 %) 0 
699G 0 1 (12.5 %) 0 
701AAT 0 0 4 (50.0 %) 
973AAT 0 2 (25.0 %) 1 (12.5 %) 
987AAT 0 0 2 (25.0 %) 
1311A 0 1 (12.5 %) 0 
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Some of the polymorphisms described above appeared to have strong 
geographic clustering (Figure 3.5). Six variations identified were seen exclusively 
among Rwandan isolates (A300C, G437A, T486C, A596C, T699G and C1311A), 
3 exclusively among DRSTP isolates (G381C, 701AAT and 987AAT) and 1 
signature that was specific for Brazilian samples (G381T). Only 3 polymorphisms 
were common between Rwanda and DRSTP (G479A, A489G and 987AAT). 
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Figure 3.5. Representation of the geographic distribution of the polymorphisms described. [The 
polymorphic sites are shown by codon]. 
 
Haplotype distribution and prevalence 
 
On the total 21 of the 24 isolates showed polymorphisms, a total of 14 different 
haplotypes were found and 10 of them leading to amino acid substitutions or 
insertions. The pfcmu allelic haplotypes present in each region are shown in Table 
3.4.  
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Thirteen isolates carried single SNP/indel, 6 displayed double SNPs/indels and 
only 2 carried triple SNPs/indels (Table 3.4). 
Unlike the Brazilian samples in which alleles had a single mutated position, 3 
out of the 8 alleles from Rwanda were multiple mutants with 2 (haplotype RW1, 
RW2 and RW4) or 3 (haplotype RW6) mutated codons/insertions. In the DRSTP 
samples, we also observed multiple mutants with 2 (haplotype DRSTP1 and 
DRSTP3) or 3 (haplotype DRSTP2) mutated codons/insertions. 
 
Table 3.4. Representation of the haplotypes observed in the different study areas. 
I100I V127V V127V R146K S160N I162I E163E K199T N233K N N N F437L
A300C G381T G381C G437A G479A T486C A489G A596C T699G 701AAT 973AAT 989AAT C1311A
zil  WT (n=1)
8)  BR1 (n=7)
anda  RW1 (n=1)
8)  RW2 (n=1)
 RW3 (n=1)
 RW4 (n=1)
 RW5 (n=1)
 RW6 (n=1)
 RW7 (n=1)
 RW8 (n=1)
STP  WT (n=2)
8)  DRSTP1 (n=2)
 DRSTP2 (n=1)
 DRSTP3 (n=1)
 DRSTP4 (n=2)
Bra
(n=
Rw
(n=
DR
(n=
 
 
 
 
 
WT: wild type. The polymorphic sites observed in this study are shown by codon (numbers refer to 
position in the gene or in the protein sequence). Amino acids are indicated with single letter code 
in capital, the nucleotide changes are indicated below). Mutations are indicated in black rectangles. 
 
3.3.2.  P. falciparum amino acid transporter gene 
We were not able to obtain the full sequence of the last amplicon of the pfaat1 
gene. Due to a repetitive AT-rich sequence in the terminal region of the gene a 
reliable sequence product could not be generated. Therefore it was not possible to 
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obtain the sequence of the coding region between nucleotide positions 1913 and 
2058.  
Sequence analysis of the pfaat1 gene revealed only 2 SNPs, 1 non-synonymous 
mutation (C773T) leading to a serine to leucine substitution (Ser258Leu) and 1 
silent mutation (C→A) at nucleotide position 1656. Both SNPs were present in all 
16 samples sequenced and were previously described in the PlasmoDB data base. 
 
The analysis of the distribution of the mutations across the protein domains 
revealed that the 2 mutations found lying in the transmembrane amino acid 
transporter protein domain family (Figure 3.6). 
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Figure 3.6 Schematic illustration of the described mutations/insertions in the context of functional 
domains of P. falciparum AAT1 protein. [The locations and the types of the 2 mutations are also 
shown]. 
 
3.4. Association between pfcmu point mutations and in vitro 
responses profiles to artemisinin derivatives 
To investigate the association between the identified mutations and in vitro 
responses profiles to antimalarial drugs, we intended to screen particular 
mutations in the remaining samples using a strategy that would be more cost-
effective than DNA sequencing and that could increase throughput. 
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The initial study of the full pfcmu gene through DNA sequencing allowed to 
uncover 5 non-synonymous mutations, and 3 asparagine insertions. Details on 
these genetic polymorphisms, and the corresponding range and mean of IC50 
values associated with each of them are presented in Table 3.5.  
 
Table 3.5. Details on polymorphisms in pfcmu gene in relation to in vitro susceptibility to 
artemisinin derivatives in P. falciparum isolates. 
 
Mutant 
allele 
Amino acid 
Change 
Total no. of mutant type alleles 
(n = 24) 
Artemisinin derivatives  
IC50 (nM) range (mean)  
    
437A Arg→Lys 1 (4 %) 9.6 
479A Ser→Asn 4 (17 %) 0.3-9.6 (6.2) 
596C Lys→Thr 1 (4 %) 0.3 
699G Asn→Lys 1 (4 %) 0.3 
701AAT + Asn 4 (17 %) 0.02-2.0 (0.9) 
973AAT + Asn 3 (13 %) 0.5-9.6 (3.9) 
987AAT + Asn 2 (8 %) 3.4-9.0 (6.2) 
1311A Phe→Leu 1 (4 %) 10.1 
 
Polymorphisms with high values of prevalence associated with higher IC50 values are in bold.  
 
From the above list of genetic polymorphisms, the 479A SNP and the 987AAT 
insertion (Table 3.5; shown in bold type), were those associated with higher IC50 
values (with a mean IC50 of 6.2 nM). Therefore, it was decided that these merited 
further analysis. However, due to time constraints and technical limitations we 
were unable to analyse the 987AAT insertion at this stage. Therefore, further work 
was carried out on screening of the G479A mutation solely. 
3.4.1.  Detection of G479A SNP by PIRA PCR and RFLP 
In order to investigate the prevalence of G479A mutation in all isolates 
available, we developed a PCR-RFLP assay. This assay was then applied to all 
isolates that were tested for the in vitro susceptibility to artemisinin derivatives. 
From Brazil we analysed 56 isolates, tested for their in vitro susceptibility to 
artemether and to artesunate. From DRSTP we studied 51 and 42 P. falciparum 
isolates tested for their in vitro susceptibility to artemether and to artesunate, 
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respectively. From Rwanda analysed 73 isolates, tested for in vitro susceptibility 
to dihydroartemisinin. 
PCR-RFLP is a simple method to identify a point mutation on the condition 
that the region of interest contains a restriction enzyme site. However, since the 
G479A point mutation does not create a natural endonuclease restriction site, we 
used the PIRA-PCR to amplify and restriction-digest the target region (see 
“Material and Methods” section for details). 
The predicted size of the PIRA-PCR product resulting from amplification with 
primers PfCLR-G479A-F and PfCLR-G479A-R is 268 bp, which can then be 
cleaved into 245 and 23 bp fragments when digested with BcuI, in the presence of 
WT allele (TAG). No cleavage is expected in the presence of mutant allele (TAA). 
The 268 and 245 bp fragments can be easily resolved on 3 % agarose gel, whereas 
the 23 bp fragment is normally difficult to visualize or discriminate from primer-
dimers. Therefore, the 245 bp band was scored as WT and 268 bp as mutant. 
Figure 3.7 shows typical results of these PIRA-PCR assays.  
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Figure 3.7 Ethidium bromide-stained 3 % agarose gel electrophoresis of BcuI digest of 
PIRA-PCR products [The products were amplified with the set of primers PfCLR-G479A-F and 
PfCLR-G479A-R. Lanes: L – DNA ladder (O’GeneRulerTM Ultra Low Range); Lane 5 – Positive 
Control (3D7); Lanes 1 to 4 and 6 to 11 – corresponds to BcuI digests of randomly selected P. 
falciparum isolates. Lanes 4, 7 and 9 corresponds to samples with the WT genotype (245 bp); 
Lanes 1, 2, 6 and 11 corresponds to samples with the mutant genotype (268 bp); Lanes 3, 8 and 10 
corresponds to samples with a mixture of genotypes (WT and mutant)]. 
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3.4.2.  Analysis of G479A mutation frequency  
To determine whether there was correlation between the G479A mutation and 
the in vitro susceptibility to artemisinin derivatives we analysed this 
polymorphism in all isolates available. In all 56 Brazil isolates tested for their in 
vitro susceptibility to artesunate and artemether we only found the WT allele. In 
Rwanda we found 83.6 % (61/73) of isolates with the WT allele, 12.3 % (9/73) 
with the mutant allele and 4.1 % (3/73) with a mixture of the two genotypes 
(mixed). In DRSTP isolates tested for in vitro susceptibility to artemether we 
found 86.2 % (44/51) of isolates with the WT allele, 11.8 % (6/51) with the 
mutant allele and only one isolate with a mixture of the two genotypes. In DRSTP 
isolates tested for in vitro susceptibility to artesunate we found 85.7 % (36/42) of 
isolates with the WT allele, 11.9 % (5/42) with the mutant allele and only one 
isolate with a mixture of the two genotypes.  
 
3.4.3.  Correlation of in vitro susceptibility to artemisinin 
derivatives and G479A polymorphism in P. falciparum 
isolates 
Results on the distribution of the G479A mutation in Rwanda and DRSTP 
isolates, according to in vitro drug responses, are shown in Figure 3.8. 
The outliers were identified by Peirce's method99 were excluded from further 
analysis. 
The mean dihydroartemisinin IC50 in Rwandan isolates harbouring the G479A 
mutation was 4.78 nM was significantly higher than that in isolates with the wild 
type allele (mean = 3.01 nM ; p =0.0207). Three isolates showed a mixture of 
alleles (Wt and Mutant), with a mean IC50 of 4.17 nM. We found no significant 
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differences for the means of the IC50 between WT and mixed isolates. Isolates 
from DRSTP, carrying the G479A mutation had a mean artesunate IC50 of 0.63 
nM compared to 0.35 nM among those with the wild type allele. Only one isolate 
showed a mixture of alleles (IC50 = 0.02). In case of in vitro susceptibility to 
artemether among DRSTP samples, mean IC50 values of 0.66 nM, 0.73nM and 
0.02nM, were observed in the mutant, WT and mixed allele groups, respectively. 
For the DRSTP isolates we found no significant differences in the means of the 
IC50 values in WT and mutant isolates or in WT and mixed isolates. All the 
isolates from Brazil had the WT allele (artesunate had a mean IC50 of 1.26 and 
artemether had a mean IC50 of 4.87). 
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Figure 3.8 Distribution of artemisinin derivatives IC50 values and the G479A mutation. [(A): 
Rwanda isolates tested for in vitro susceptibility to dihydroartemisinin; (B) DRSTP isolates tested 
for in vitro susceptibility to artesunate; (C) DRSTP isolates tested for in vitro susceptibility to 
artemether. Wild type: G479; Mutant, A479; Mixed, G479 + A479. Individual values (circles) and 
mean values (bars) are shown. Outliers are marked as open circles].  
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3.5. Population genetic analysis of the P. falciparum 
clathrin mu adaptor gene 
We analysed DNA polymorphisms of the nucleotide sequence data using the 
DnaSP software (http://www.ub.edu/dnasp/) in order to gain insights into the 
levels of genetic diversity. 10 haplotypes and 9 polymorphic sites were identified 
among the 24 P. falciparum individuals studied for which complete DNA 
sequence was available. Collectively, 8 segregating sites in Rwanda, 3 in DRSTP 
and 1 in Brazil were identified. These grouped into 7, 5 and 2 different haplotypes, 
respectively. 
Genetic diversity indices for each parasite population are presented in Table 3.6. 
The theta value of all P. falciparum isolates was 0.00129 with the overall π 
diversity 0.00085 ± 0.00011. Haplotype diversity (Hd), nucleotide diversity per 
site (π) and theta value showed regional variations. Of the 3 locations, the Rwanda 
was found to be the most polymorphic population (π = 0.00132, SD = 0.00017). 
The mean value of nucleotide diversity of DRSTP isolates was 0.00050 ± 0.00011 
with θ value of 0.00166. The Brazil population displayed the lowest values for all 
the indices of genetic diversity and the lowest theta estimates (Table 3.6). 
 
Table 3.6: Estimates of genetic diversity per sample. 
 
 N S H Hd π θ(S) 
Brazil 8 1 2 0.250 ± 0.180 0.00013 ± 0.00010 0.00021 
Rwanda 8 8 7 0.964 ± 0.077 0.00132 ± 0.00017 0.00166 
DRSTP 8 3 4 0.750 ± 0.139 0.00050 ± 0.00013 0.00062 
All samples 24 9 10 0.870 ± 0.045 0.00085 ± 0.00011  0.00129 
 
Legend: N: sample size; S: number of segregating sites; H: number of haplotypes; Hd: haplotype 
diversity (i.e. expected heterozygosity based on haplotype frequency) and its standard deviation, 
SD; π: nucleotide diversity (average number of nucleotide substitution per site between pairs of 
sequences in the data set) and SD; θ(S): θ from S. 
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The human malaria parasite P. falciparum has acquired resistance to most 
drugs it has encountered, including the recently deployed Artemisinin 
Combination Therapy, on which much hope had been laid31,32,80,101. The spread of 
artemisinin resistance could significantly impair global malaria-control efforts. 
Therefore, the need for identification and monitoring of genes and mutations 
giving rise to resistance to this class of drugs is immediate. Dealing with this issue 
is now imperative, before the spread of resistance become uncontainable. 
Resistance to artemisinin derivatives has been correlated with mutation-driven 
alterations in the drug’s putative chemotherapeutic target, the SERCA-type 
ATPase protein of P. falciparum (PfATPase6)57 and amplification of the multi-
drug resistance 1 gene, Pfmdr153,77,78. However, no correlation was found between 
these genes and in vivo resistance to artemisinins in the first confirmed cases of 
resistance along the Thai/Cambodian border31,80. Thus we still lack validated 
genetic markers to monitor the evolution of artemisinin resistance in natural 
parasite populations. 
The P. falciparum chloroquine resistance transporter gene (pfcrt) and the 
pfmdr1 gene have been linked to 4-aminoquiloline resistance51,71,72. Several in 
vivo studies showed absolute selection of the pfcrt K76T mutant allele in 
therapeutic failure. However, the presence of parasites having this allele was not 
always predictive of the clinical outcome or predictive of in vitro resistance 66-68. 
Furthermore, the relationship between pfmdr1 and chloroquine resistance remains 
unclear and is a matter of controversy67,73-75. This suggests involvement of 
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additional genetic loci modulating chloroquine resistance. For this reason, more 
studies are necessary to elucidate the mechanisms of resistance to this class of 
drugs.  
Our group has used the Plasmodium chabaudi rodent model to investigate the 
genetic basis of antimalarial drug resistance. By using a novel paradigm based on 
genome-wide genetics and genomics approaches, we have recently identified a 
number of previously undescribed genetic markers of resistance to different drugs. 
Two of these genes are involved in mediating artemisinin resistance, namely a de-
ubiquitinating enzyme (UBP1)89 and a clathrin mu adaptor gene (pfcmu) (Cravo 
et al., unpublished). Additionally, one further mutation in an amino acid 
transporter gene (pfaat1) was shown to underlie chloroquine resistance. Given the 
pressing requirement to contain the spread of artemisinin resistance in natural 
parasite populations and gain new insights into the dynamics of resistance to 
4-aminoquiloline, the assessment and validation of new molecular markers for 
drug surveillance is now a top priority. However, the importance of the markers 
identified in the rodent model in modulating susceptibility to the different drugs in 
the human malaria parasite has not been assessed yet. In this context, the objective 
of this work was to characterize the pfcmu and pfaat1 genes in natural parasite 
populations of P. falciparum. To achieve this, we used an extensive collection of 
previously sampled isolates of P. falciparum from three endemic regions (Rwanda, 
DRSP and Brazil) which were tested for in vitro sensitivity to several drugs. In 
these samples we investigated the correlation between the presence of mutations in 
the pfcmu and pfaat1 genes and the in vitro sensitivity to artemisinin derivatives 
and to 4-aminoquinolines, respectively. 
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In previous studies, the same samples above had been inspected for mutations 
in a number of previously characterized candidate genes (pfcrt, pfmdr1, 
pfATPase6, pfubp1), but no statistically significant association between the 
response to drugs  and the genes analysed was found90-92,102,103, suggesting that 
other molecular determinants are likely to be involved in modulating the parasite’s 
susceptibility to the compounds tested. 
 
4.1. Characterization of the P. falciparum amino acid 
transporter gene 
Analysis of the full length sequence of pfaat1 in 16 isolates from Rwanda and 
DRSTP, indicated that the gene appears to be highly conserved, with only two 
SNPs present among the isolates examined, namely. i) a serine to leucine 
substitution at nucleotide 773; and one silent mutation (C1656A). Alternative 
explanations to justify this high degree of conservation are discussed below. 
A biological argument is that the high level of conservation may be critical for 
the function of the protein. Alternatively, the pfaat1 gene could be positioned in a 
genomic region of reduced variation. It has been demonstrated that genetic 
diversity suffers from natural degrees of variation across the genome among 
different chromosomes and/or particular loci104. The source of this variation is not 
fully understood in all cases, but it may be that the pfaat1 gene could be 
positioned in a genomic region of intrinsically reduced variation. Well 
characterized sources of reduced genetic variation across the genome are areas that 
have undergone selective sweeps, such as those observed around the chloroquine 
locus, pfcrt105. In these regions, not only the target gene suffers from limited 
diversity, but also all the linked loci surrounding it. The pfaat1 gene may lie in 
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one of these areas and may have, consequently, been exposed to the effects of 
selective pressures that ended up contributing to decrease its allelic diversity. 
Finally, the relatively small number of samples sequenced may be other 
explanation for the homogeneity observed. Thus, additional studies would be of 
great value to better understand the relative importance of biologic and/or 
epidemiologic factors responsible for the limited allelic diversity observed in this 
study. 
The two mutations identified were found in all isolates sequenced, independent 
of the samples’ response to 4-aminoquinolines. These data indicate that variations 
in susceptibility to 4-aminoquinolines in P. falciparum may not determinate by 
changes in the sequence of the pfaat1 gene. Therefore it is possible that P. 
falciparum may reveal an alternative mechanism of resistance to those of P. 
chabaudi, as in the case of the pfcrt gene84. 
 
4.2. Characterization of the P. falciparum clathrin mu 
adaptor gene 
DNA sequencing from 24 isolates distributed among the three regions, revealed 
nucleotide substitutions at 9 different positions, with five of these SNPs causing 
the following predicted amino acid shifts: R146K, S160N, K199T, N233K and 
F437L. A second source of genetic diversity detected in the pfcmu gene was 
sequence length variation due to the presence of indels (insertions/deletions). 
Three indels at different positions within the coding sequence were detected, all of 
them leading to a 3-nucleotide insertion of an AAT codon that corresponded to an 
insertion of an asparagine residue. 
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The F437L mutation, and the 325N and 330N insertions are predicted to lie in 
the conserved “adaptador complexes medium subunit family” domain (also known 
as “mu homology” domain) of the protein, possibly affecting its function. The 
other mutations/indels are expected to be positioned in a protein region with no 
known functional domains. One way to interpret this observation is that mutations 
can easily accumulate in the less conserved region, since they will not 
significantly affect the function of the protein. However, the biological 
significance of the above mutations/indels is difficult to forecast in the absence of 
functional assays. 
 
Analysis of pfcmu DNA sequences showed that mutant alleles of this gene were 
present in 88% (21/24) of the isolates analysed. There was a clear geographic 
heterogeneity in the frequency and type of polymorphisms found and none of the 
mutations were found in P. falciparum isolates from all three study areas. In 
Brazil, the only mutation present was synonymous (G381T) and was highly 
predominant (88% - 7/8). Polymorphisms in this gene were more frequent in P. 
falciparum populations from Africa, where eight and six mutated sites were found 
in Rwanda and the DRSTP, respectively. Three of these mutations were detected 
in isolates from both study areas (G479A, A489G and 978AAT). The other 
polymorphisms appear to have strong geographic clustering, with six variants 
identified exclusively among Rwanda isolates (A300C, G437A, T486C, T699G 
and C1311A) and three among DRSTP isolates (G381C, 701AAT and 987AAT). 
The G381T mutation is a specific signature of the Brazilian samples.  
All measures of genetic polymorphisms showed regional variation among the 
three P. falciparum populations. Pfcmu nucleotide and haplotype (gene) diversity 
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values in Brazil (π = 0.00013; Hd = 0.250) are much lower than those obtained in 
Rwanda (π = 0.00132; Hd = 0.964) and DRSTP (π = 0.00050; Hd = 0.750). These 
findings are congruent with other studies of genetic variation in the P. falciparum 
population106,107,108. At a global scale, dramatic differences in P. falciparum 
population structure in different locations have been reported. A possible 
explanation for these findings is the high transmission levels observed in Africa as 
compared with Asia and South America. High transmission levels are correlated 
with malaria prevalence and are a direct measure of the parasite reproduction. 
Thus, it is expected that higher transmission areas will maintain populations with 
higher effective population size were diversifying natural selection could be a 
important aspect for sustaining the parasite polymorphisms107. An alternative 
explanation is that P. falciparum most likely originated in Africa exhibits more 
genetic diversity in this continent109. The derived populations in Southeast Asia 
and the Americas may have less genetic diversity because of bottlenecks during 
the colonization process110. The geographic distribution of transmission levels 
correlate with history, thus both assumptions make the same predictions and are 
not mutually exclusive. 
Understanding the genetic structure of P. falciparum is important for predicting 
how fast particular phenotypes, such as drug resistance, will arise and spread 
within and between populations. 
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4.2.1. Correlation of in vitro susceptibility to 
artemisinin derivatives and G479A polymorphism 
in P. falciparum isolates 
Pfcmu genotyping and population genetics studies demonstrated that the gene’s 
diversity is variable between different geographical regions. Considering that this 
variation can pose a confounder effect in the relation between pfcmu SNPs/indels 
and parasite drug susceptibility it may be necessary to further analyse phenotypic 
associations with particular mutations within a region. Consequently, we 
investigated the prevalence of the G479A mutation in all isolates tested for their in 
vitro susceptibility to artemisinin derivatives from Brazil, Rwanda and DRSTP. In 
Brazilian isolates only the WT allele was detected. This allele was found in more 
than 80 % of the isolates and the mutant allele in ≈ 12% of the isolates from 
Rwanda and DRSTP. We only found 3 and 1 isolate with a mixture of genotypes 
in Rwanda and DRSTP, respectively. 
A significant association was observed between G479A mutation and the in 
vitro dihydroartemisinin responses in isolates from Rwanda. The mean 
dihydroartemisinin IC50 in Rwandan isolates harbouring the G479A mutation was 
significantly higher (p < 0.05) than that in isolates with the wild type allele. 
Whereas, the differences in IC50 values between the pfcmu WT and mutant in 
DRSTP isolates were not statistically significant. One possible explanation for this 
finding is that the direct correlation between point mutations and artemisinin 
susceptibility may be dependent of the geographic origin of the parasites. 
Alternatively, the isolates from the two countries could have been exposed to 
different antimalarial drug pressures, leading to different in vitro responses to 
artemisinins. 
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The G479A mutation leads to the replacement of a Serine by an Asparagine, 
substitution that could affect the protein function and ultimately affect the parasite 
susceptibility to artemisinin derivatives. Besides G479A mutation, other two 
polymorphisms (987AAT and 1311A) could be associated with high IC50 values 
for artemisinins (> 6 nM), but these were not explored in detail. These two 
mutations result in an insertion or amino acid change, respectively, at the 
conserved mu homology domain of the protein.  
Collectively, all of the above polymorphisms are not indicators of resistance, 
but may reveal the initial stages of reduced susceptibility, with a subsequent 
process of stepwise mutation. The evolution of resistance to artemisinins can be a 
stepwise process during which the accumulation of mutations might modulate the 
response to artemisinins. The first step is the acquisition of some mutations that 
confer no “real resistance” on its own, followed by subsequent a mutation which 
augments resistance levels. Therefore, it is possible that some of these mutations 
are the necessary first step that allows the other changes to be selected.  
These findings suggest that analysis of the pfcmu gene may be a potential tool 
for the surveillance of antimalarial drug resistance to artemisinins. However, more 
in-depth studies are necessary to determine the implications of these and other 
genetic polymorphisms on in vitro drug susceptibility to artemisinin derivatives. 
 
It is known that natural parasite populations of P. falciparum vary significantly 
with respect to their susceptibility to artemisinin derivatives91,111. However, the 
clinical meaning of this phenotype variability is difficult to determine as there is 
no established in vitro cut-off value for resistance to artemisinins. The results of 
the in vitro drug tests to artemisinin derivatives performed in our samples 
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corroborate these findings, IC50 values ranged from 0.02 to 14.3 nM90-92. A 
possible explanation for these variations could be the result of cross-resistance to 
other antimalarial drugs, that as been proposed in several other studies81,111,112 . 
Considering that our samples were collected before the implementation of ACTs, 
the diversity in pfcmu may represent the baseline variation of the gene without 
artemisinin selection in these regions. In alternative, the inappropriate use of 
artemisinin compounds in the studied areas may also explain this finding. The 
natural occurring variation in pfcmu may constitute a starting point for artemisinin 
driven selection of resistant variants. Therefore, it is important to identify the 
presence of SNPs in pfcmu for future monitoring of potential rise and spread of 
artemisinin resistance based on modifications in this gene.  
 
4.3. Possible model of PfCMU mediated artemisinin 
resistance  
During the blood stage of malaria infection, the parasite internalizes and 
degrades massive amounts of haemoglobin (Hb) in the digestive vacuole (DV). 
One of the processes recently described for the delivery of Hb into the DV was the 
mechanism mediated by membrane-bound vesicles (clathrin coated vesicles)113. 
These membrane-bound vesicles have specific coat proteins (such as clathrin) that 
are important for cargo selection and direction of transport between donor and 
acceptor compartments. Clathrin coats contain both clathrin (acts as a scaffold) 
and adaptor proteins (AP), that link clathrin to receptors in coated vesicles. AP 
complexes connect cargo proteins and lipids to clathrin at vesicle budding sites, as 
well as binding accessory proteins that regulate coat assembly and 
disassembly114-116. Interestingly, the pfcmu gene encodes a clathrin mu adaptor 
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protein that is a subunit of the AP2 adaptor, associated with the plasma membrane 
and responsible for endocytosis. Consequently, mutations in this protein may alter 
the adaptor binding specificity affecting the transport of Hb by clathrin coated 
vesicles to the DV. 
The implications of these mutations to artemisinin resistance phenotypes are 
unclear in the absence of further studies. We suggest a highly speculative model 
(Figure 4.1) for the involvement of pfcmu mutation in resistance to artemisinins 
based on the biological process of Hb internalization/degradation in the parasite’s 
DV and in the mechanism of action of artemisinins. Recent work has proposed 
that artemisinin trioxane derivatives rapidly accumulate in the DV and are 
activated by neutral lipid-associated haem117. The formation of the later depends 
on Hb-clathrin coated vesicles. Once inside the DV, the Hb-clathrin coated 
vesicles are digested, releasing amino acids, lipid components (phospholipids) and 
free haem. The phospholipids are afterwards degraded and its components are 
reconstituted to form neutral lipid-associated haem117,118. We propose that 
mutations in the pfcmu gene may impair Hb transport into DV via clathrin coated 
vesicles. By using alternative pathways of Hb uptake, the parasite could have 
access to Hb without the release of phospholipids (required for artemisinin 
activation), consequently modulating its response to artemisinin. 
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Figure 4.1. Putative mechanism of PfCMU mediated artemisinin resistance. Legend: RBC: Red 
Blood Cell; 1) Haemoglobin (Hb) transport into the digestive vacuole (DV) by a mechanism 
mediated by clathrin coated vesicles; 2) Digestion of Hb-clathrin coated vesicles with the release of 
amino acids, phospholipids (PL) and free haem. Phospholipids are subsequently degraded and 
reconstituted to form neutral lipid-associated haem. 3) Activation of artemisinin (ART) by neutral 
lipid-associated haem. 
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Chapter 5: Conclusions and future perspectives 
We identify and characterize the P. falciparum cmu and aat1 genes and 
investigate its possible involvement in the in vitro responses to artemisinin 
derivatives and 4-aminoquinolies, respectively. 
 
The Pfaat1 gene appears to be highly conserved and no correlations were 
found between this gene and the in vitro resistance to 4-aminoquinolines. P. 
falciparum may reveal an alternative mechanism of resistance to those of P. 
chabaudi. 
In contrast to Pfaat1, the Pfcmu gene was genetically diverse, with some of the 
identified SNPs and indels showing geographical specificity. This diversity may 
provide useful baseline data for future studies on this candidate drug resistance 
locus. 
We found a significant association between the pfcmu 479A genotype in 
Rwanda samples and the in vitro sensitivity to dyhidroartemisinin. These 
constitute new findings to suggest that polymorphisms in pfcmu can be involved in 
P. falciparum defence mechanisms against artemisinin derivatives. Thus, further 
assessment of the gene in artemisinin responses is a top priority, in the context of 
effective surveillance of artemisinin resistance. 
In conclusion, malaria is a major public health problem which is further 
enhanced by P. falciparum drug resistance. The understanding of the mechanisms 
of resistance to antimalarial drugs is crucial. This thesis has shed light on the 
Chapter 5 – Conclusion and Future Perspectives 
complex issue of P. falciparum resistance to artemisinins and will foster new 
studies to understand its mechanisms. 
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